Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA-888 (miR-888) is a member of the microRNA family, a class of small non-coding RNAs (typically ~22 nucleotides) that regulate gene expression post-transcriptionally. miR-888 is primate-specific, X-linked, and has been identified as highly upregulated in aggressive forms of prostate cancer, promoting cell proliferation and migration by suppressing tumor suppressor genes. Elevated miR-888 levels in prostatic secretions and urine are associated with high-grade prostate cancer, indicating its promise as a diagnostic and prognostic biomarker, as well as a potential therapeutic target[2].
miR-888 negatively regulates the expression of target mRNAs by binding to their 3′UTRs, leading to repression of their translation or mRNA degradation, particularly suppressing tumor suppressor genes such as RBL1 and SMAD4[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA-888 (miR-888).